Onco Actu du 18 juin 2018

	3.3 Prévention - Vaccins
The Impact of the National HPV Vaccination Program in England Using the Bivalent HPV Vaccine: Surveillance of Type-Specific HPV in Young Females, 2010–2016 [Journal of Infectious Diseases] Eight years after the introduction of a national HPV vaccination program, substantial declines have occurred in HPV16/18 and HPV31/33/45. The prevalence of other high-risk HPV types has not changed.
HPV vaccine has almost wiped out infections in young women, figures show [The Telegraph] The data shows declines across five high-risk HPV types in total, which cause around 90 per cent of cervical cancer cases.
HPV vaccine cuts cancer-causing infection [BBC News] HPV infections decreased in women aged 16 to 21 by 86% between 2010 and 2016 data from Public Health England show. It comes as newspapers say the vaccine may soon be offered to boys too.
	4.1 Dép., diag. & prono. - Prostate
Prostate Biopsy Complications Deter Patients From Re-Biopsy [Prostate Cancer Advisor] Of 4939 men (aged 50 to 75 years) who underwent prostate biopsy at 2 years in the REDUCE trial, 5.3% experienced a complication such as hematuria, urinary tract infection (UTI), acute urinary retention (AUR), or hematospermia.
	4.2 Dép., diag. & prono. - Génome
Breast cancer researcher warns against online genetic tests [Imperial College] Our biggest concern with this direct to consumer test is the potential for false reassurance.
Are Genetic Testing Sites the New Social Networks? [NY Times] At-home genetic testing services have gained significant traction in the past few years. 23andMe, which costs $99, has over five million customers, according to the company; AncestryDNA (currently $69), over 10 million.
	5.1 Traitements - Pré-clinique
Cancer researchers target the dormant cells that seed tumours [Nature] Dormant cancer cells are rare, and they are difficult to sift from the trillions of normal cells in the body. For years, researchers lacked the tools to study them, says cancer researcher Julio Aguirre-Ghiso of the Icahn School of Medicine at Mount Sinai in New York City. But that is beginning to change.
	5.12.6 Immunothérapies - AMM
Bristol-Myers’ Opdivo ushers in a new era as the first I-O therapy approved in China [FiercePharma] Different from its world-first and U.S.-first indication of melanoma, Opdivo goes directly to the larger and more lucrative lung cancer market with this Chinese approval, for patients with previously chemo-treated advanced non-small cell lung cancer to be exact.
Bristol-Myers wins the frenzied race to a first approval for a PD-1/L1 checkpoint in China as regulators hustle up a quick OK [EndPoints] Bristol-Myers, which has been fighting a losing war with Merck for dominance in the NSCLC field in the US, wrapped their Phase III with a predominantly Chinese group of patients late last year, hustling the positive results to regulators as they looked to flank their rivals in Asia.
China National Drug Administration Approves Country’s First Immuno-Oncology Agent, Opdivo (nivolumab injection), for Previously Treated Non-Small Cell Lung Cancer (NSCLC) [BMS] The first and only PD-1 inhibitor approved in China opens a new era of Immuno-Oncology treatment for a type of lung cancer.
	5.4 Traitements - Economie
NICE dogs Roche's Perjeta again, this time in postsurgery breast cancer patients [FiercePharma] NICE isn’t the only group not to find Roche’s Perjata postsurgery data somewhat underwhelming. When details dropped at last year’s American Society of Clinical Oncology (ASCO) meeting—and later when the combo picked up FDA approval—industry watchers and analysts labeled the performance “weak.”
	5.9.3 EHA
Despite FDA hold, Epizyme’s tazemetostat posts positive interim data [FierceBiotech] However, the data for the mutant group has yet to mature, since the clinical hold prevented it from fully enrolling and the patients in that group started treatment later than those in the wild-type group, Epizyme CEO Robert Bazemore said.
Epizyme Reports Positive Updated Interim Data from Phase 2 Study of Tazemetostat in Patients With Relapsed or Refractory Follicular Lymphoma at the Congress of the European Hematology Association (EHA) [Epizyme] Durable Clinical Responses and Progression-Free Survival Observed in Patients With or Without an EZH2 Activating Mutation.
Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone Reduces the Risk of Disease Progression by 46% Versus Pomalidomide/Dexamethasone Alone in Patients with Relapsed or Refractory Multiple Myeloma [BMS] Primary endpoint of progression-free survival met for the combination of Empliciti plus pomalidomide and low-dose dexamethasone.
Novartis study of real-world data concludes Jakavi is associated with a reduction in risk of death and dangerous blood clots for patients with rare blood cancer [Novartis] Comparison of Jakavi® (ruxolitinib) vs. best available therapy presented at EHA suggests reduced risk of death in patients with inadequately controlled polycythemia vera.
Novartis JULIET trial of Kymriah demonstrates more than one-year durability of responses in adults with relapsed or refractory DLBCL [Novartis] With eight months of additional follow-up, response rates remained consistent with previous reports and the safety profile was maintained with no emergence of new safety signals.
Winners and losers at #EHA18: Shares mostly slide as data from a range of prominent biotechs fail to wow investors [EndPoints] The conference, which attracts something like 10,000 hematologists, is on its second day — and many of this year’s newsmakers are working in the competitive field of blood cancers.
	6.10 Politiques
‘Our NHS is there for us, now it’s time to stand with them’ [Cancer Research UK] Last week, we launched our Shoulder to Shoulder Against Cancer Campaign to push for the Government to train and employ more staff to diagnose and treat cancers earlier. Over 80 voluntary Cancer Campaigns Ambassadors went to Parliament to meet their MPs and ask them to sign a joint letter to the Prime Minister.
	6.4 Médico-éco
Breast cancer patients are being denied 'life-changing' reconstructive surgery, research shows [The Telegraph] The new figures, from clinical commissioning groups across the country, show many are only allowing women t have surgery if they do soon after their mastectomy, with others refusing to carry out more than one operation, if efforts are not successful.
Hundreds of breast cancer patients 'denied reconstruction' [BBC News] Breast Cancer Now says the restrictions are "arbitrary" and put patients' quality of life at risk. But it found evidence that some procedures were being denied. Breast surgeons have also raised concerns and are calling for equal access to services.
	6.7.1 IA/bioinformatique
Microsoft’s purchase of GitHub leaves some scientists uneasy [Nature] They fear the online platform will become less open, but other researchers say the buyout could make GitHub more useful.
	6.9 Controverses
Theranos founder Elizabeth Holmes indicted for alleged fraud, out as CEO [STAT] The criminal charges filed by federal prosecutors allege that Holmes and Balwani bilked investors out of hundreds of millions of dollars while also defrauding doctors and patients through years of lies that put thousands of people in personal danger.